Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type3 E: c# z; }' Y4 j# I) X
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
" B) a3 F4 c/ _% C+ Author Affiliations, ?/ }- W. H; J5 z6 o! X+ D
. H7 D% I% k- e3 u* j; s
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
8 Q8 M- G, U+ A3 B& I2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan . v; k9 B! X( t7 v$ w
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
; }" |) z" z2 I) X% O* C. |4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ) u+ h9 u# v' Z% @/ k4 G9 d
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
; `3 v9 o* J& w: O: E6 l5 C6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
+ @4 s: S* z: T8 k6 c6 Y6 ]7Kinki University School of Medicine, Osaka 589-8511, Japan
- q1 L& [ v8 G/ S3 }2 E8Izumi Municipal Hospital, Osaka 594-0071, Japan
3 K) `4 A8 h. \1 g, N6 S8 V: B9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
* q' \% L* k. W! e) b* xCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp . C! f @$ W* D
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. + l! g* t) w; U$ C& p" s& [7 W
$ N9 k; f+ e9 u/ U7 A$ W" T
|